Drug Type Small molecule drug |
Synonyms Bevonium Metilsulfate, Bosporon, Chlortenoxicam + [20] |
Target |
Action inhibitors |
Mechanism COX inhibitors(Cyclooxygenases inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Denmark (01 Jan 1997), |
Regulation- |
Molecular FormulaC13H10ClN3O4S2 |
InChIKeyWLHQHAUOOXYABV-UHFFFAOYSA-N |
CAS Registry70374-39-9 |
Start Date02 Mar 2024 |
Sponsor / Collaborator- |
Start Date20 Jul 2022 |
Sponsor / Collaborator- |
Start Date31 Mar 2022 |
Sponsor / Collaborator- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01866 | Lornoxicam |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Bursitis | Japan | 02 Feb 2001 | |
Cervicobrachial syndrome | Denmark | - | 01 Jan 1997 |
Low Back Pain | Denmark | - | 01 Jan 1997 |
Neuralgia | Denmark | - | 01 Jan 1997 |
Osteoarthritis | Denmark | - | 01 Jan 1997 |
Pain | Denmark | - | 01 Jan 1997 |
Pain, Postoperative | Denmark | - | 01 Jan 1997 |
Periarthritis | Denmark | - | 01 Jan 1997 |
Rheumatic Diseases | Denmark | - | 01 Jan 1997 |
Rheumatoid Arthritis | Denmark | - | 01 Jan 1997 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Headache | Phase 2 | United States | 01 Dec 2005 | |
Migraine Disorders | Phase 2 | United States | 01 Dec 2005 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
Phase 2 | 219 | (Lornoxicam) | ywpeplgaow(aoaexrfkop) = bqtlcauvly tflpmgomrz (rjiwgfaujy, 6.75) View more | - | 29 Nov 2012 | ||
Placebo (Placebo) | ywpeplgaow(aoaexrfkop) = usdmksfard tflpmgomrz (rjiwgfaujy, 7.84) View more |